Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

New This Week On Slingshot Insights SA Premium Service: 1/21/2019

|Includes: Allergan plc (AGN), GILD, ICPT, IMGN
Summary

This week we have Expert Calls on: IMGN, GILD, ICPT, AGN.

This series of instablog posts will highlight the most recently executed transcripts being added to the “Become the Smart Money” , Slingshot Insights Seeking Alpha Premium service. In these blog posts we will give you a bit more information about the subject matter experts we interviewed, the topics covered, and relevant companies. We hope that these brief overviews, combined with our free content and articles, will display what we believe is the content’s unique value to our members. Please don’t hesitate to directly ask us questions at any time via SeekingAlpha Direct message or email to info@slingshotinsights.com.

Why Do Expert Research?

While many individuals we speak to are unaware of the role expert interviews play for many professional investors, it is a $600mm industry. Many funds pay in excess of $100,000 a year just for a relationship with an expert network and over a thousand dollars per call. While these numbers sound staggering, many investors consider them well worth the money. Slingshot Insights’ sharing model has transformed the price of these calls for our customers and now we are making them even more affordable to you on the SeekingAlpha Marketplace for only $75 per month.

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these : Link

Transcript 1: Another Opinion: Understanding the potential of IMGN's Mirvetuximab soravtansine (IMGN853) in the ovarian cancer landscape.

Ticker: IMGN

Who's the Expert?

  • Clinical Associate Professor at Jefferson Medical College & Director, Division of Gynecologic Oncology Department of Obstetrics and Gynecology at the the Helen F. Graham Cancer.
  • Practices in NCI Comprehensive Community Cancer Center with 3 GYO doctors each managing 60 Ovarian Cancer patients at a time.
  • Clinical focus on gynecologic malignancies as well as advanced laparoscopic and robotic surgery including cancer staging and radical hysterectomy; prescribes, administers and follows patients requiring chemotherapy for advanced or recurrent malignancies, or those at a high risk of recurrence.

Interview Goal: To explore the market potential of Immunogen's Mirvetuximab soravtansine (IMGN853), an antibody-drug conjugate currently in development for patients with folate receptor alpha (FRα)-positive cancer.

Link to original project page on Slingshot Insights with questions asked: link

Transcript 2: Examining new compounds in development in the NASH and PBC landscape

Ticker: GILD , ICPT, AGN

Who's the Expert?

  • Professor and Chairman of our Department of Medicine at MUSC.
  • Clinical research interests revolve around establishing management strategies for patients with common gastrointestinal problems, especially GI bleeding, and the overall direction of these studies has been to help establish national patient management guidelines.
  • Has authored more than 200 scientific papers dealing with GI-related topics and has presented many invited lectures at gastroenterology and hepatology symposia around the United States and throughout the world.

Interview Goal: This conversation will discuss the current compounds in development and competitive landscape for NASH and PBC patients.

Link to original project page on Slingshot Insights with questions asked: link

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.